Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model.

Cell reports. Medicine·2026
Same author

Domain arrangement-driven immunogenicity of a computationally designed mRNA vaccine targeting PPE68, IrtA, and PE9 of Mycobacterium tuberculosis.

Scientific reports·2026
Same author

Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells.

Frontiers in immunology·2026
Same author

The influence of murine cytomegalovirus infection on susceptibility to mycobacterial infection.

iScience·2026
Same author

Evaluation of 1<sup>st</sup> WHO anti-malaria reference reagent for competition ELISA harmonisation and development of ADAMSEL analytical platform.

Biologicals : journal of the International Association of Biological Standardization·2025
Same author

MetE: a promising protective antigen for tuberculosis vaccine development.

Frontiers in immunology·2025

Related Experiment Video

Updated: Jun 1, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Tuberculosis vaccines in clinical trials.

Rosalind Rowland1, Helen McShane

  • 1The Jenner Institute, Old Road Campus Research Building, Oxford University, Oxford, OX3 7DQ, UK.

Expert Review of Vaccines
|May 25, 2011
PubMed
Summary

Developing new tuberculosis (TB) vaccines is crucial for global health. Research is exploring improved BCG vaccination methods and novel vaccines to combat the TB epidemic.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a significant global health challenge, necessitating effective control strategies.
  • The current bacille Calmette-Guérin (BCG) vaccine offers partial protection, indicating the potential for improved TB vaccines.
  • A need exists for enhanced vaccination strategies to combat the global TB epidemic.

Purpose of the Study:

  • To review the current landscape of TB vaccine development, including modifications to BCG and novel vaccine candidates.
  • To highlight the ongoing clinical evaluations of various TB vaccine approaches.
  • To identify critical requirements for the successful development and licensure of new TB vaccines.

Main Methods:

  • Review of ongoing clinical trials for TB vaccines.

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Related Experiment Videos

Last Updated: Jun 1, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

  • Analysis of different vaccine strategies: BCG modifications, BCG boosters, BCG replacements, and therapeutic vaccines.
  • Identification of essential components for vaccine development: animal models, biomarkers, and efficacy testing sites.

    • Main Results:

    • Multiple TB vaccine candidates are in clinical development, including live attenuated vaccines, subunit vaccines, and therapeutic vaccines.
    • Clinical trials are assessing both improved BCG administration and novel vaccine formulations.
    • The development pathway requires validated animal models, immunological biomarkers, and large-scale field trial capabilities.

    Conclusions:

    • Advancing TB vaccine development requires a multi-faceted approach, combining innovative vaccine designs with robust evaluation methods.
    • Successful licensure of new TB vaccines hinges on validated preclinical models, reliable biomarkers of protection, and capacity for large-scale clinical trials.
    • Improved vaccination strategies are essential for controlling the global TB epidemic.